Ausgabe 1/2018
Inhalt (27 Artikel)
Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study
Mark O’Loughlin, Xavier Andreu, Simonetta Bianchi, Ewa Chemielik, Alicia Cordoba, Gábor Cserni, Paulo Figueiredo, Giuseppe Floris, Maria P. Foschini, Päivi Heikkilä, Janina Kulka, Inta Liepniece-Karele, Peter Regitnig, Angelika Reiner, Ales Ryska, Anna Sapino, Aliaa Shalaby, Elisabeth Specht Stovgaard, Cecily Quinn, Elaine M. Walsh, Vicky Zolota, Sharon A. Glynn, Grace Callagy
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)
Jame Abraham, Robert Coleman, Anthony Elias, Frankie Ann Holmes, Kevin Kalinsky, Muaiad Kittaneh, Elyse Lower, Reshma Mahtani, E. Terry Mamounas, Mark Pegram, Charles Vogel
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer
M. L. Telli, D. G. Stover, S. Loi, S. Aparicio, L. A. Carey, S. M. Domchek, L. Newman, G. W. Sledge, E. P. Winer
Construction of a novel multi-gene assay (42-gene classifier) for prediction of late recurrence in ER-positive breast cancer patients
Ryo Tsunashima, Yasuto Naoi, Kenzo Shimazu, Naofumi Kagara, Masashi Shimoda, Tomonori Tanei, Tomohiro Miyake, Seung Jin Kim, Shinzaburo Noguchi
The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway
Hisako Ono, Yoshihiro Sowa, Mano Horinaka, Yosuke Iizumi, Motoki Watanabe, Mie Morita, Emi Nishimoto, Tetsuya Taguchi, Toshiyuki Sakai
Genetic dissection of the BRCA2 promoter and transcriptional impact of DNA variants
Eugenia Fraile-Bethencourt, Alberto Valenzuela-Palomo, Beatriz Díez-Gómez, Mar Infante, Mercedes Durán, Germán Marcos, Enrique Lastra, Susana Gómez-Barrero, Eladio A. Velasco
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer
Erik J. Blok, Charla C. Engels, Geeske Dekker-Ensink, Elma Meershoek-Klein Kranenbarg, Hein Putter, Vincent T. H. B. M. Smit, Gerrit-Jan Liefers, James P. Morden, Judith M. Bliss, R. Charles Coombes, John M. S. Bartlett, Judith R. Kroep, Cornelis J. H. van de Velde, Peter J. K. Kuppen
Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE)
Timothy J. Williamson, Susan M. Love, Jessica N. Clague DeHart, Alexandra Jorge-Miller, Leah Eshraghi, Heather Cooper Ortner, Annette L. Stanton
BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients
Marius Wunderle, Paul Gass, Lothar Häberle, Vivien M. Flesch, Claudia Rauh, Mayada R. Bani, Carolin C. Hack, Michael G. Schrauder, Sebastian M. Jud, Julius Emons, Ramona Erber, Arif B. Ekici, Juliane Hoyer, Georgia Vasileiou, Cornelia Kraus, Andre Reis, Arndt Hartmann, Michael P. Lux, Matthias W. Beckmann, Peter A. Fasching, Alexander Hein
Risk of ischemic heart disease after radiotherapy for ductal carcinoma in situ
C. Wadsten, A.-K. Wennstig, H. Garmo, Greger Nilsson, Carl Blomqvist, Lars Holmberg, Irma Fredriksson, F. Wärnberg, M. Sund
A double-blind, randomised trial of a polyphenolic-rich nail bed balm for chemotherapy-induced onycholysis: the UK polybalm study
Robert Thomas, Madeleine Williams, Michael Cauchi, Saul Berkovitz, Sarah A. Smith
Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer
Aditya Bardia, Ayca Gucalp, Noashir DaCosta, Nashat Gabrail, Michael Danso, Haythem Ali, Kimberly L. Blackwell, Lisa A. Carey, Joel R. Eisner, Edwina S. Baskin-Bey, Tiffany A. Traina
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial
Cesar A. Santa-Maria, Aditya Bardia, Amanda L. Blackford, Claire Snyder, Roisin M. Connolly, John H. Fetting, Daniel F. Hayes, Stacie C. Jeter, Robert S. Miller, Anne Nguyen, Katie Quinlan, Gary L. Rosner, Shannon Slater, Anna Maria Storniolo, Antonio C. Wolff, Jane Zorzi, Nora Lynn Henry, Vered Stearns
Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer
G. Hoste, K. Punie, H. Wildiers, B. Beuselinck, I. Lefever, E. Van Nieuwenhuysen, S. N. Han, P. Berteloot, N. Concin, R. Salihi, I. Vergote, P. Neven
Incorporation of the technologist’s opinion for arbitration of discrepant assessments among radiologists at screening mammography
Angela M. P. Coolen, Joost R. C. Lameijer, Adri C. Voogd, Luc J. Strobbe, Marieke W. J. Louwman, Vivianne C. G. Tjan-Heijnen, Lucien E. M. Duijm
Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001–2016)
Benjamin Daniels, Belinda E. Kiely, Sarah J. Lord, Nehmat Houssami, Christine Y. Lu, Robyn L. Ward, Sallie-Anne Pearson
SNP rs2071095 in LincRNA H19 is associated with breast cancer risk
Ping Cui, Yanrui Zhao, Xinlei Chu, Na He, Hong Zheng, Jiali Han, Fengju Song, Kexin Chen
Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists
Yonina R. Murciano-Goroff, Anne Marie McCarthy, Mirar N. Bristol, Peter Groeneveld, Susan M. Domchek, U. Nkiru Motanya, Katrina Armstrong
Incidence and risk factors for congestive heart failure in patients with early breast cancer who received anthracycline and/or trastuzumab: a big data analysis of the Korean Health Insurance Review and Assessment service database
Jung Yoon Choi, Eun Young Cho, Yoon Ji Choi, Jeong Hyeon Lee, Seung Pil Jung, Kyu Ran Cho, Chul Yong Kim, Yeul Hong Kim, Kyong Hwa Park
Associations of dietary intake and supplement use with post-therapy cognitive recovery in breast cancer survivors
Zhezhou Huang, Yan Shi, Pingping Bao, Hui Cai, Zhen Hong, Ding Ding, James Jackson, Xiao-Ou Shu, Qi Dai
Gene expression in triple-negative breast cancer in relation to survival
Shuyang Wang, Alicia Beeghly-Fadiel, Qiuyin Cai, Hui Cai, Xingyi Guo, Liang Shi, Jie Wu, Fei Ye, Qingchao Qiu, Ying Zheng, Wei Zheng, Ping-Ping Bao, Xiao-ou Shu
Predictors of surveillance mammography outcomes in women with a personal history of breast cancer
Kathryn P. Lowry, Lior Z. Braunstein, Konstantinos P. Economopoulos, Laura Salama, Constance D. Lehman, G. Scott Gazelle, Elkan F. Halpern, Catherine S. Giess, Alphonse G. Taghian, Janie M. Lee
Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database
Maryam Elmi, Arash Azin, Ahmad Elnahas, David R. McCready, Tulin D. Cil
Effect of glucocorticoid use on survival in patients with stage I–III breast cancer
Ching-Hung Lin, Po-Ya Chuang, San-Lin You, Chun-Ju Chiang, Chiun-Sheng Huang, Ming-Yang Wang, Ming Chao, Yen-Shen Lu, Ann-Lii Cheng, Chao-Hsiun Tang
Impact of high-deductible insurance on adjuvant hormonal therapy use in breast cancer
Christine Y. Lu, Fang Zhang, Anita K. Wagner, Larissa Nekhlyudov, Craig C. Earle, Matthew Callahan, Robert LeCates, Xin Xu, Dennis Ross-Degnan, J. Frank Wharam
Tamoxifen-induced fatty liver disease in a Caucasian patient
Karel Eechoute, Ron H. J. Mathijssen, Teun van Gelder
Treatment-induced early menopause and the protective role of gonadotropin-releasing hormone agonists during chemotherapy
Francesca Poggio, Benedetta Conte, Matteo Lambertini